My Treatment Approach: Metastatic Castration-Resistant Prostate Cancer

Andrew Armstrong, MD, and Matthew Manning, MD, review the profiles of three patients with metastatic castration-resistant prostate cancer (mCRPC) and discuss how they would have approached their treatment, given recent advances in radiotherapy and other options in the field.

EP. 1: The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

April 17th 2023

Andrew Armstrong, MD, and Matthew Manning, MD, explain how the treatment options and typical patient outcomes in mCRPC have changed over history.

EP. 2: Approved Treatment Options for Patients with mCRPC

April 17th 2023

Medical oncologist Andrew Armstrong, MD, details the available treatment options for patients with mCRPC, and how recommendations vary by prior therapy and mutation status.

EP. 3: Patient Profile: A 78-Year-Old Man with mCRPC

April 26th 2023

Dr Andrew Armstrong presents a profile of a 78-year-old man with mCRPC with a single PSMA-avid bone metastasis and asks Dr Manning how he would treat the patient in question.

EP. 4: Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy

April 26th 2023

Drs Manning and Armstrong discuss the best treatment approaches for a patient with mCRPC and disease progression in the bone after initial radiotherapy for metastatic disease.

EP. 5: Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases

May 1st 2023

Radiation oncologist Matthew Manning, MD, shares the patient profile of a 72-year-old man with mCRPC receiving palliative treatment with radium-223.

EP. 6: Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC

May 1st 2023

Drs Armstrong and Manning review the safety and efficacy data from the ALSYMPCA trial of radium-223 in patients with mCRPC.

EP. 7: Considerations for Treatment Selection for Patients with Disease Progression on Radium-223

May 1st 2023

A medical oncologist and radiation oncologist share clinical insight on how they might approach subsequent treatment selection in patients with mCRPC who have disease progression on or after radium-223.

EP. 8: Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases

May 1st 2023

Centering discussion on a patient profile of mCRPC with asymptomatic bone metastases, experts share best approaches to treating and optimizing outcomes for such patients, including supplement recommendations to prevent bone fractures.

EP. 9: Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

May 8th 2023

Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.

EP. 10: Closing Thoughts on the Future of mCRPC Treatment

May 8th 2023

Matthew Manning, MD, and Andrew Armstrong, MD, discuss the remaining unmet needs in mCRPC, clinical trials and novel agents to look out for, and share practical advice for other clinicians treating patients with the disease.